HPV Vaccination Catch-Up in Adults 27–45: What the Evidence Shows for Shared Decision-Making
Synthesis of 10 studies — including efficacy trials, the ACIP GRADE analysis, a 2025 decision aid RCT, and guideline positions — evaluating the evidence for HPV vaccination in mid-adults and how to implement shared clinical decision-making in family medicine. Moderate evidence base, through 2025.
This is an original evidence synthesis. See References for source studies.
One-Minute Takeaway
One-Minute Takeaway
- The ACIP recommends HPV vaccination catch-up in adults 27–45 based on shared clinical decision-making — not as a routine or universal recommendation — because most adults in this age range have already been exposed to HPV and population-level benefit is minimal, though selected individuals may benefit.
- In the pivotal efficacy trial, the 4-valent HPV vaccine demonstrated 88.7% per-protocol efficacy in women aged 24–45 against a composite of persistent infection, genital warts, and precancerous lesions related to vaccine-type HPV; intention-to-treat efficacy was substantially lower at 47.2%, reflecting prior exposure in this age group.
- Adults most likely to benefit include those not yet sexually active, those entering a new sexual relationship after a long monogamous period, MSM, transgender individuals, and immunocompromised persons — though no validated tool exists to identify who will benefit individually.
- Insurance coverage for adults over 26 is inconsistent — the ACA mandates cost-free coverage for routine ACIP recommendations but not for shared clinical decision-making recommendations, meaning patients may face out-of-pocket costs exceeding $500 for the three-dose series.
Why HPV Vaccination Catch-Up in Adults 27–45 Matters
HPV is the most common sexually transmitted infection in the United States, with approximately 14 million new infections annually. Persistent infection with high-risk HPV types causes six distinct cancers — cervical, oropharyngeal, anal, vulvar, vaginal, and penile — responsible for an estimated 37 000 cancer diagnoses annually. Nearly half of all new HPV infections occur in adults aged 25 and older. Despite the extraordinary success of adolescent HPV vaccination (an 80% decrease in cervical cancer precursors was documented in vaccinated cohorts by 2025), a substantial proportion of adults aged 27–45 were never vaccinated, having been too old when the programme launched in 2006.
For family physicians, this topic presents a unique challenge. Unlike routine childhood immunisations, HPV catch-up in mid-adults is not a universal recommendation — it requires an individualised conversation that weighs potential benefit against the likelihood of prior exposure, cost barriers, and limited population-level impact. A 2023 CDC survey found that while most family physicians were aware of the ACIP shared decision-making recommendation, many reported uncertainty about which patients to approach and what to emphasise during the conversation. The 2025 HPV DECIDE trial demonstrated that structured decision aid tools can reduce this decisional conflict, but real-world implementation remains patchy.
What Evidence Was Reviewed
This synthesis draws on the clinical trials that informed the 2018 FDA approval and 2019 ACIP recommendation, the GRADE evidence analysis, provider knowledge surveys, a 2025 decision aid RCT, and guideline/policy positions from the ACIP, ACS, and ACA framework.
| Study | Design | n | Population | Key Finding | Quality |
|---|---|---|---|---|---|
| Castellsagué 2011 (FUTURE III) | RCT | 3253 | Women 24–45 yr | Per-protocol efficacy 88.7%; ITT efficacy 47.2% against vaccine-type HPV endpoints | High |
| ACIP GRADE Analysis 2019 | Systematic evidence review | NR | Adults 27–45 yr (16 publications) | Moderate evidence for efficacy in women; low evidence in men; moderate for safety | High |
| ACIP Evidence to Recommendation 2019 | EtR framework | NR | Adults 27–45 yr | Voted 10:4 for SCDM; unanimous against routine/catch-up recommendation | High |
| Meites 2019 (MMWR) | ACIP policy note | NR | Updated recommendations all ages | Catch-up through 26 yr for all; SCDM for 27–45 yr; not recommended >45 yr | High |
| Supplemental immunobridging data | Non-inferiority studies | NR | Mid-adults vs young adults | Non-inferior immunogenicity in mid-adults compared to young adults | Moderate |
| Thompson 2025 (HPV DECIDE) | RCT (Solomon 4-group) | 612 | Unvaccinated adults 27–45 yr | Decision aid reduced decisional conflict, improved knowledge, intentions, and self-efficacy | Moderate |
| Markowitz 2023 (CDC survey) | Cross-sectional survey | 753 | FM, IM, OB-GYN physicians | Most aware of SCDM recommendation; many uncertain about whom to approach | Moderate |
| ACS 2025 Position | Policy statement | NR | Adults 27–45 yr | ACS does not endorse SCDM recommendation due to low effectiveness and cost concerns | N/A |
| KFF HPV Factsheet 2024 | Policy analysis | NR | US population | Insurance coverage for >26 yr inconsistent; ACA mandate does not cover SCDM recommendations | N/A |
| FDA 9vHPV Approval 2018 | Regulatory decision | NR | Adults 27–45 yr | Approved Gardasil 9 for ages 9–45 based on efficacy and immunobridging data | High |
Key Findings on HPV Vaccination Catch-Up in Adults 27–45
Vaccine Efficacy Is Real but Substantially Attenuated by Prior Exposure
The critical distinction for this age group is between per-protocol and intention-to-treat efficacy. In the pivotal FUTURE III trial (Castellsagué 2011), women aged 24–45 who were HPV-naïve at enrolment showed 88.7% per-protocol efficacy (95% CI 78.1–94.8) against the combined endpoint of persistent infection, genital warts, and precancerous lesions related to vaccine-type HPV. This demonstrates that the vaccine works well in adults who have not yet encountered the target HPV types. However, the intention-to-treat efficacy — which includes all enrolled women regardless of baseline HPV status — was only 47.2% (95% CI 33.5–58.2). This roughly 40-percentage-point drop reflects the reality that many sexually active mid-adults have already been infected with one or more vaccine-type HPV strains and cannot benefit from vaccination against those specific types.
Immunobridging studies showed that antibody responses to the 9-valent vaccine in mid-adults were non-inferior to those in younger adults, confirming that the immune response is adequate when the vaccine is given to this age group. The ACIP GRADE analysis rated the overall evidence for efficacy as moderate (Level 2) in women and low (Level 3) in men, where efficacy data are inferred rather than directly demonstrated.
Why ACIP Chose Shared Decision-Making, Not Routine Recommendation
The ACIP’s 2019 decision was notably contentious, passing only 10–4 with the work group unanimously opposing a routine or catch-up recommendation for this age range. The rationale centres on three factors. First, population-level benefit is minimal because most adults 27–45 have already been exposed to HPV through sexual activity. Second, cost-effectiveness modelling did not favour universal vaccination in this age group. Third, the practical challenge of identifying who benefits individually — without a reliable biomarker for prior exposure — means that universal vaccination would treat predominantly already-immune individuals at significant cost.
The shared clinical decision-making framework is distinct from routine recommendations in a fundamental way: the default is not to vaccinate. The ACIP explicitly states that “most U.S. adults ages 27 through 45 years will not need to be vaccinated against HPV.” The clinician’s role is to identify the subset of patients who may benefit and engage them in an informed discussion about the potential value and limitations of catch-up vaccination. The American Cancer Society has gone further, choosing not to endorse even the shared decision-making recommendation, citing low effectiveness and the potential for cost burden in this age group.
The ACIP guidance identifies several groups of adults 27–45 who may benefit from catch-up vaccination. These include: individuals who have never been sexually active (who would derive per-protocol-level benefit); those entering a new sexual relationship after a long monogamous period (who may encounter new HPV types); men who have sex with men (MSM), who have higher rates of anal HPV infection and anal cancer; transgender individuals; and persons with immunocompromising conditions, who may have impaired natural clearance of HPV. However, it is important to recognise that no validated screening tool or risk calculator exists to identify which mid-adults will benefit individually. The conversation is inherently probabilistic — the clinician is helping the patient weigh the likelihood of benefit (which decreases with increasing lifetime sexual partners) against cost and the modest inconvenience of a three-dose series.
This is perhaps the most practically important barrier for family physicians and patients. Under the ACA, private insurers are required to cover ACIP-recommended vaccines without cost-sharing — but this mandate applies to routine and catch-up recommendations, not to shared clinical decision-making recommendations. This means that HPV vaccination for adults over 26 may not be covered as preventive care by many insurance plans. The three-dose Gardasil 9 series can cost $500–$700 or more out of pocket. Coverage varies widely by insurer; some plans do cover it if a physician documents medical necessity, while others explicitly exclude it for patients over 26. This cost barrier should be transparently discussed during the shared decision-making conversation, as it materially affects the value proposition for patients with limited financial resources.
The safety of HPV vaccines in adults 27–45 is well-established. The ACIP GRADE analysis rated overall evidence for harms as Level 2 (moderate). Postlicensure surveillance data encompassing over 29 million doses of HPV vaccine have not identified safety concerns beyond those already documented in younger populations. Common adverse effects include injection site pain, swelling, and redness (reported in the majority of recipients), along with mild systemic symptoms such as headache, fatigue, and low-grade fever. Syncope has been reported following HPV vaccination, prompting a recommendation for 15 minutes of observation post-injection. Serious adverse events are rare and occur at rates comparable to placebo in clinical trials. The safety profile does not differ meaningfully between mid-adults and younger recipients, and safety is not a barrier to vaccination in this age group.
The 2025 HPV DECIDE trial (Thompson et al.) tested a structured patient decision aid against a standard information fact sheet in a randomised Solomon 4-group design with 612 unvaccinated adults aged 27–45. The decision aid significantly reduced decisional conflict (the primary outcome) and improved knowledge, vaccination intentions, self-efficacy, and perceived risk compared with the control condition. The tool was rated as acceptable by participants across both sexes. This is the first rigorously evaluated decision support tool designed specifically for mid-adult HPV vaccination and could provide a scalable framework for implementing the shared decision-making recommendation in primary care. However, the study measured immediate attitudinal outcomes — whether the tool actually increases vaccination uptake or reduces HPV-related disease in practice remains to be evaluated.
Provider Knowledge and Practice Gaps
A 2023 CDC-administered survey of 753 physicians (family medicine, internal medicine, OB-GYN) found that while most were aware of the ACIP shared decision-making recommendation, a substantial proportion reported uncertainty about which patients to prioritise for the conversation and what points to emphasise. Despite the COVID-19 pandemic, at least a third of physicians in each specialty reported having more HPV vaccine shared decision-making discussions than before the recommendation. However, the survey also revealed that many physicians lacked confidence in their shared decision-making skills specifically for HPV vaccination in this age group — a finding that underscores the need for practical communication frameworks and tools in primary care.
Quality & Consistency of Evidence
What the Evidence Does Not Show
Several clinically relevant questions remain unresolved for family physicians counselling mid-adults about HPV vaccination.
Individual-level prediction of benefit. No clinical tool, biomarker, or algorithm can reliably identify which mid-adults are HPV-naïve for vaccine-type strains and would therefore derive per-protocol-level benefit. Cervical HPV testing only detects current high-risk infections and does not capture cleared infections or immunity. This uncertainty is central to the shared decision-making conversation.
Efficacy data in men aged 27–45. The pivotal efficacy trial enrolled only women. Efficacy in men aged 27–45 is inferred from immunobridging data and efficacy against anal endpoints in younger male populations. Direct efficacy evidence in mid-adult men, particularly for oropharyngeal cancer prevention, does not exist.
Cost-effectiveness in the era of the 9-valent vaccine. Most cost-effectiveness analyses that informed the ACIP decision used the 4-valent vaccine data. Whether the broader coverage of the 9-valent vaccine (protecting against 7 oncogenic types rather than 2) changes the cost-effectiveness calculation for mid-adults has not been formally modelled in a US context.
Cancer prevention in mid-adults specifically. All cancer incidence and mortality reductions attributed to HPV vaccination come from adolescent and young adult cohorts. Whether vaccination at ages 27–45 will translate into measurable cancer prevention at a population level is unknown and may not be knowable for decades.
Practical Implications
Based on the current evidence, the following framework may support family physicians in implementing the shared clinical decision-making recommendation for HPV vaccination in adults 27–45. These are evidence-based considerations — they are not directive recommendations to vaccinate all mid-adults.
Evidence Grade & Bottom Line
Overall Evidence Grade: Moderate (Efficacy in HPV-naïve mid-adults) / Limited (Population-level effectiveness and cancer outcomes)
The vaccine works well in mid-adults who have not been previously exposed to vaccine-type HPV strains (per-protocol efficacy 88.7%), and immunogenicity is non-inferior to younger adults. However, population-level effectiveness is substantially lower due to prior exposure, cost-effectiveness is uncertain, and cancer prevention in this age group has not been demonstrated. This evidence profile — strong individual efficacy but weak population benefit — is precisely why ACIP chose shared decision-making rather than universal recommendation.
Family physicians should neither dismiss HPV vaccination in mid-adults as useless nor promote it as universally beneficial. The evidence supports a carefully targeted conversation with patients most likely to benefit — those with fewer prior sexual exposures, those anticipating new partners, MSM, transgender individuals, and immunocompromised persons — while transparently addressing the cost, the impossibility of knowing individual benefit with certainty, and the continuing importance of cervical cancer screening regardless of vaccination status.
- HPV vaccination is safe and immunogenic in adults 27–45, with per-protocol efficacy of 88.7% in HPV-naïve women — but ITT efficacy of only 47.2% in the general mid-adult population.
- ACIP recommends shared clinical decision-making, not routine vaccination, for this age group because most adults have already been exposed and population benefit is minimal.
- Insurance coverage for adults over 26 is inconsistent and patients may face costs exceeding $500 for the complete series — a factor that should be addressed transparently in the conversation.
- No trial has demonstrated cancer prevention from HPV vaccination initiated in mid-adulthood; benefit is inferred from prevention of persistent infection and precancerous lesions.
- Structured decision aids such as HPV DECIDE show promise for supporting clinicians in implementing the shared decision-making recommendation effectively.
Article Information
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Meites E, Szilagyi PG, Chesson HW, et al. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68(32):698–702. DOI: 10.15585/mmwr.mm6832a3
- CDC. Evidence to recommendations for HPV vaccination of adults, ages 27 through 45 years. ACIP Evidence to Recommendation Framework. Updated 2024. Available at: cdc.gov
- CDC. Grading of Recommendations Assessment, Development and Evaluation (GRADE) for use of HPV vaccine in adults ages 27 through 45 years. Updated 2024. Available at: cdc.gov
- Castellsagué X, Muñoz N, Pitisuttithum P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer. 2011;105(1):28–37. DOI: 10.1038/bjc.2011.185
- Thompson EL, Luningham J, Alkhatib SA, et al. Testing an HPV vaccine decision aid for 27- to 45-year-old adults in the United States: a randomized trial. Med Decis Making. 2025;45(2):147–159. DOI: 10.1177/0272989X241305142
- Markowitz LE, Gedlinske AM, Gee J, et al. Health care provider knowledge around shared clinical decision-making regarding HPV vaccination of adults aged 27–45 years in the United States. Vaccine. 2023;41(16):2650–2655. DOI: 10.1016/j.vaccine.2023.02.051
- CDC. ACIP shared clinical decision-making recommendations. Updated May 2025. Available at: cdc.gov
- KFF. The HPV vaccine: access and use in the U.S. Updated October 2024. Available at: kff.org
- American Cancer Society and ACS CAN. Letter to ACIP regarding HPV vaccine recommendations. June 2025. Available at: fightcancer.org
- FDA. Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) prescribing information. Whitehouse Station, NJ: Merck & Co.; 2018 (supplemental approval for ages 27–45).